Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and 18F-FDG PET/CT
-
Published:2021-12
Issue:12
Volume:11
Page:
-
ISSN:2044-5385
-
Container-title:Blood Cancer Journal
-
language:en
-
Short-container-title:Blood Cancer J.
Author:
Cho Hee JeongORCID, Jung Sung-Hoon, Jo Jae-Cheol, Lee Yoo Jin, Yoon Sang Eun, Park Sung-SooORCID, Kim Do YoungORCID, Shin Ho-Jin, Mun Yeung-ChulORCID, Yi Jun Ho, Kim Hyo Jung, Kim Da Jung, Lee Ho Sup, Bae Sung Hwa, Hong Chae Moon, Jeong Shin Young, Min Jung-Joon, Sohn Sang Kyun, Min Chang-Ki, Kim KihyunORCID, Lee Je-JungORCID, Moon Joon HoORCID, Cho Hee Jeong, Jung Sung-Hoon, Jo Jae-Cheol, Lee Yoo Jin, Yoon Sang Eun, Park Sung-Soo, Kim Do Young, Shin Ho-Jin, Mun Yeung-Chul, Yi Jun Ho, Kim Hyo Jung, Kim Da Jung, Lee Ho Sup, Bae Sung Hwa, Hong Chae Moon, Jeong Shin Young, Min Jung-Joon, Sohn Sang Kyun, Min Chang-Ki, Kim Kihyun, Lee Je-Jung, Moon Joon Ho,
Abstract
AbstractIn multiple myeloma (MM), a high number of focal lesions (FL) detected using positron emission tomography/computed tomography (PET/CT) was found to be associated with adverse prognosis. To design a new risk stratification system that combines the Revised International Staging System (R-ISS) with FL, we analyzed the data of 380 patients with newly diagnosed MM (NDMM) who underwent 18F-fluorodeoxyglucose (18F-FDG) PET/CT upon diagnosis. The K-adaptive partitioning algorithm was adopted to define subgroups with homogeneous survival. The combined R-ISS with PET/CT classified NDMM patients into four groups: R-ISS/PET stage I (n = 31; R-ISS I with FL ≤ 3), stage II (n = 156; R-ISS I with FL > 3 and R-ISS II with FL ≤ 3), stage III (n = 162; R-ISS II with FL > 3 and R-ISS III with FL ≤ 3), and stage IV (n = 31; R-ISS III with FL > 3). The 2-year overall survival rates for stages I, II, III, and IV were 96.7%, 89.8%, 74.7%, and 50.3%. The 2-year progression-free survival rates were 84.1%, 64.7%, 40.8%, and 17.1%, respectively. The new R-ISS/PET was successfully validated in an external cohort. This new system had a remarkable prognostic power for estimating the survival outcomes of patients with NDMM. This system helps discriminate patients with a good prognosis from those with a poor prognosis more precisely.
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology
Reference30 articles.
1. Kyle RA, Rajkumar SV. ASH 50th anniversary review. Blood. 2008;111:2962–72. 2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585–98. 3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20. 4. Kunacheewa C, Orlowski RZ. New drugs in multiple myeloma. Annu Rev Med. 2019;70:521–47. 5. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33:2863–69.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|